Indian culture is consistently acknowledged for its harmonious nature between humans and non-humans. People have carried the culture with magnificent changes over the years and spread awareness about veterinary healthcare. The India veterinary healthcare market is projected to register a CAGR of 7.98 percent during the forecast period, with revenue of approximately $1,083.13 million in 2020 and expected to reach $1,697.15 million by 2026. Adisan Laboratories is a significant veterinary medicine manufacturing company with great potential to produce quality products to keep pets or animals healthy.
Adisan Laboratories, which established its business in 2008 as a partnership firm which later-on changed its constitution to Private Limited Company, caters to significant multinationals like Elanco India, Bayer, Novartis, Elanco Thailand, De Laval, Sanofi, Boehringer, Virbac, HUVE Pharma, Norel, Intas, IIL, Vetbiochem India, Ashish Life Science and Alivira Animal Health, for Ectoparaceticides and Poultry Disinfectants in Liquid & Powder Forms and Liquid Orals for veterinary use. For several years, the company has been successfully meeting all the requirements and standards set by multinational companies. Adisan Laboratories has been majorly focusing on B2B business and is a regular supplier to multinationals for the last decade.
Adisan Laboratories, located in Pune, Maharashtra, has been granted GMP by FDA Maharashtra and accredited as ISO 9001:2015 certified company. Adisan Laboratories has two separate units, which cater to external and disinfectants in liquid & powder form, spot-ons and another unit for liquid oral form. Adisan Laboratories has diversified into liquid & powder feed supplements, milking machinery cleaners, hygiene products and more. Adisan Laboratories has launched Pet Food Brand ‘Gobblez’ through its sister concern, which recently has come into the Maharashtra and Goa market.
Considering the varied impact of the COVID-19 pandemic on various markets regarding its growth and outbreak, Aditya Devadhar, MD of Adisan Laboratories, shares his thoughts saying, “While a few industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. Hence, the market is anticipated to be impacted during the pandemic due to the reduced veterinary visits, along with the shortage of veterinary medicines during the outbreak of COVID-19, steep increase in transport charges and anti-China sentiments has brought majority of focus to Indian manufacturers. Additionally, India is agricultural country, so veterinary business in India will always grow. Also, supply disruption and medicine shortages of veterinary medicines had been observed in several countries, primarily due to the temporary lockdowns of manufacturing sites, export bans, and increased demand for medicine”.
Aditya further adds, “Due to lockdowns and online education, most parents having one child have adopted pets, which has increased demand on pet products. This may be a new trend seen in future to see home education and work from home, which will surely increase Pet Medicine and food business”.
Products Adhering To Global Standards
Adisan is a B2B manufacturer of Ectoparaceticides like cypermethrin, Deltamethrin, Amitraz, Flumethrin, Fipronil, Spot-ons, Liquid & Powder disinfectants, Liquid Orals, and more. It has all the data validated regarding batch records, testing protocols and product specifications. So, their customers are able to start marketing their products in the domestic & export markets, and register the product in the export market as fast as possible.
The most important expectation of all multinational customers is to adhere to strict c-GMP guidelines and upgrade systems at all times with new regulatory requirements. One of the main objectives of Adisan is to keep upgrading itself to meet the international standards set by key players. All the customers always expect the best quality product. Adisan assures it and delivers quality products, as each member of Adisan is committed to improving the quality, whether it is in process or services. Adisan has an in-house QC laboratory with all the modern equipment, Micro lab and QA systems to check for quality at each step.
Adisan is known for its quality products in the market such as Liquid External Emulsifiable Concentrates like Cypermethrin, Deltamethrin, Amitraz, Pour on solutions like Flumethrin, Fipronil, Spot-on Like Fipronil, Fipronil with S-Methoprene, Selamectin, and Imidacloprid with Permethrin. Liquid Disinfectants for Poultry with all various combinations of Quaternary Ammonium Compounds like BKC, Gluteraldehyde, TBTO, DIDAC, PHMB, and PHMG. Other one is Powder Disinfectants like Potassium Monopursulphate powder, Liquid orals clear liquids or suspensions with one or more actives like Enrofloxacin, Enro with Bromo, Albendazole, Fenbendazole, Levofloxacin, Ivermectin, Oxyclozanide and many more.
All the customers always expect the best quality product, Adisan assures it and delivers quality products, as each member of Adisan is committed to improving the quality whether it is in process or services
To stand with the quality standards, Adisan follows a quality policy. The policy says that the company will continuously strive to improve the quality of products & services to satisfy the customer needs, strict delivery schedules and will continuously improve the effectiveness of the quality management system. To achieve the policy, adisan has put several objectives like – Every member of Adisan is committed to improve the Quality, whether in process or services. Quality improvement is a continuous ongoing process with always scope for more significant achievements. Adisan believes in cost control without sacrificing quality. Cost control can be achieved with improved efficiency and involvement of all concerned. By periodically assessing customer and regulatory requirements and upgrading products, processes and services.
What Differentiates Adisan Laboratories?
While Adisan Laboratories persists in its uniqueness due to its strategic location, different units for oral & external forms, well-equipped quality control lab, c-GMP complied documentation, B2B business model, supportive in product development and proactive & supportive approach towards customer’s requirements. Adisan started manufacturing liquid external applications for veterinary use. Over the period, Adisan has the facility to manufacture liquid external applications, liquid Disinfectants, powder disinfectants, and liquid oral solutions & suspensions for veterinary use. Within ten years, the company has come to a level wherein it supplies to the top pharmaceutical giants as a CMOs. Currently, Adisan is exporting to various countries viz. Thailand, Russia, Bhutan, Singapore, Ethiopia, Kenia, Sri Lanka, West Indies, Nepal, Senegal, Uzbekistan, Rwanda, Afghanistan, and Azerbaijan through their esteemed customers. Adisan is registered in Bhutan, Nepal, Ethiopia and Thailand.
“Due to lockdowns and online education, most parents having one child have adopted pets, which has increased demand on pet products”
Aditya’s vision and understanding of business have brought a turnover of Adisan from $60,000 to $2.5 million per annum in a short span. Aditya’s perseverance towards quality and positive approach towards upgradation of a facility as per c-GMP has brought rewards over time. Adisan can proudly say that the ethical approach of Aditya has brought more international customers and business, which in-turn became the main reason for the growth of Adisan. It provided more options in terms of products to its customers. It has brought the product range of Adisan from 10 products to more than 100 products only in 10 years.
With an optimistic vision, Aditya concluded with the outlook of Adisan Laboratories, which is to become a significant domestic pet food manufacturing brand in India through its sister concern Adisan Pet Foods, and start a manufacturing company abroad. The company also looks forward to achieve WHO GMP Certification, start ointment manufacturing, bolus manufacturing, grow to Rs. 100 crore Topline, Exporting to 50 countries, and filing IPO in 2026.
.jpg "Artificial Intelligence to Revolutionize Advanced Chip Design")
